New therapeutic promises in the treatment of depression and schizophrenia

Drug News and Perspectives

Volumn 21, Issue 10, 2008, Pages 581-592

  Dhir, Ashish ^a   Kulkarni, S K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 2 AMINOPHOSPHOHEPTANOIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; ACPT 1; AGOMELATINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTISAUVAGINE 30; CELECOXIB; CORTICOTROPIN RELEASING FACTOR; CP 316311; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIZOCILPINE; KETAMINE; LIOTHYRONINE; MIFEPRISTONE; N [2 [4 (4 CYANOPHENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PLACEBO; REBOXETINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EVENING DOSAGE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; SOMNOLENCE; TRANSCRANIAL MAGNETIC STIMULATION; URINE RETENTION; VAGUS NERVE STIMULATION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; HUMANS; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS;

EID: 62649102864     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (123)

1. Wong, M.L. and Licinio, J. Research and treatment approaches to depression. Nat Rev Neurosci 2001, 2(5): 343-51.
2. Wong, M.L. and Licinio, J. From monoamines to genomic targets: A paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004, 3(2): 136-51.
3. Kessler, R.C., Berglund, P., Demler, O. et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289(23): 3095-105.
4. Greist, J.H., Mundt, J.C. and Kobak, K. Factors contributing to failed trials of new agents: Can technology prevent some problems? J Clin Psychiatry 2002. 63(2): 8-13.
5. Artigas, F., Romero, L., de Montigny, C. and Blier, P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996, 19(9): 378-83.
6. Fava, M. and Davidson, K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996, 19(2): 179-200.
7. Lieberman, D.J. The burden of illness and response to treatment. XXVI CINP Congr (July 13-17, Munich) 2008, IS-10.
8. Greenberg, P.E., Kessler, R.C., Birnbaum, H.G., Leong, S.A., Lowe, S.W., Berglund, P.A. and Corey-Lisle, P.K. The economic burden of depression in the United States: How did it change between 1990 and 2000? J Clin Psychiatry 2003, 64(12): 1465-75.
9. Murray, C.J. and Lopez, A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349(9064): 1498-504.
10. Sheps, D.S. and Sheffield, D. Depression, anxiety, and the cardiovascular system: the cardiologist's perspective. J Clin Psychiatry 2001, 62(8): 12-16.
11. Rumsfeld, J.S. and Ho, P.M. Depression and cardiovascular disease: A call for recognition. Circulation. 2005, 111(3): 250-53.
12. Wells, K.B., Stewart, A., Hays, R.D. et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989, 262(7): 914-19.
13. Stepaniuk, J., Ritchie, L., and Tuokko, H.A. Neuropsychiatric impairments as predictors of mild cognitive impairment, dementia, and Alzheimer's disease. Am J Alzheimers Dis Other Demen 2008, 23(4): 326-33.
14. Ballard, C., Bannister, C., Solis, M., Oyebode, F. and Wilcock, G. The prevalence, associations and symptoms of depression amongst dementia sufferers. J Affect Disord 1996, 36(3-4): 135-44.
15. Kokmen, E., Beard, C.M., O'Brien, P.C. and Kurland, L.T. Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc 1996, 71(3): 275-82.
16. Licinio, J. and Wong, M.L. Depression, antidepressants and suicidality: A critical appraisal. Nat Rev Drug Discov 2005, 4(2): 165-71.
17. Vijayakumar, L. Suicide and mental disorders in Asia. Int Rev Psychiatry 2005, 17(2): 109-14.
18. Holtzheimer, P.E. 3rd, Nemeroff, C.B. Advances in the treatment of depression. NeuroRx 2006, 3(1): 42-56.
19. Trivedi, M.H., Morris, D.W., Grannemann, B.D. and Mahadi, S. Symptom clusters as predictors of late response to antidepressant treatment. J Clin Psychiatry 2005, 66(8): 1064-70.
20. Delgado, P.L. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000, 61(6): 7-11.
21. Ressler, K.J. and Nemeroff, C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000, 12(1): 2-19
22. Delgado, P.L. How antidepressants help depression: Mechanisms of action and clinical response. J Clin Psychiatry 2004, 65(4): 25-30.
23. Nemeroff, C.B. Recent advances in the neurobiology of depression. Psychopharmacol Bull 2002, 36(2): 6-23.
24. Morilak, D.A. and Frazer, A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004, 7(2): 193-218.
25. Alcaro, A., Huber, R. and Panksepp, J. Behavioral functions of the mesolimbic dopaminergic system: An affective neuroethological perspective. Brain Res Rev 2007, 56(2): 283-321.
26. Hardeland, R., Poeggeler, B., Srïnivasan, V., Trakht, I., Pandi-Perumal, S.R. and Cardinali, D.P. Melatonergic drugs in clinical practice. Arzneimittelforschung 2008, 58(1): 1-10.
27. Hajak, G. Counteracting circadian rhythm disturbances in depressed patients. XXVI CINP Congr (July 13-17, Munich) 2008, IS-02.
28. Hardela, R., Poeggeler, B., Srinivasan, V., Trakht, I., Pandi-Perumal, S.R. and Cardinali, D.P. Melatonergic drugs in clinical practice. Arzneimittelforschung 2008, 58(1): 1-10.
29. San, L. and Arranz, B. Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008, 23(6): 396-402.
30. Gorwood, P.A. Evidence for agomelatine's antidepressant efficacy. XXVI CINP Congr (July 13-17, Munich) 2008, IS-02.
31. Millan, M.J., Brocco, M., Gobert, A. and Dekeyne, A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005, 177(4): 448-58.
32. Fuchs, E., Simon, M. and Schmelting, B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 2006, 21(1): S17-20.
33. Racagni, G., Riva, M.A. and Popoli, M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol 2007, 22(2): S9-S14.
34. Hamon, M. Innovative pharmacological approach in depression XXVI CINP Congr (July 13-17, Munich) 2008, IS-02.
35. Bánki, M.C. Agomelatine: the first "melatoninergic" antidepressant. Neuropsychopharmacol Hung 2006, 8(3): 105-12.
36. Zupancic, M. and Guilleminault, C. Agomelatine: A preliminary review of a new antidepressant. CNS Drugs 2006, 20(12): 981-92.
37. Selye, H. The stress of Life. New York: McGraw-Hill, 1956, Rev. Ed, 1976.
38. Hindmarch, I. Beyond the monoamine hypothesis: Mechanisms, molecules and methods. Eur Psychiatry 2002, 17(3): 294-99.
39. Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J. and Monteggia, L.M. Neurobiology of depression. Neuron 2002, 34(1): 13-25.
40. Krackow, E. and Rudolph, K.D. Life stress and the accuracy of cognitive appraisals in depressed youth. J Clin Child Adolesc Psychol 2008, 37(2): 376-8.
41. Holsboer, F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001, 62(1-2): 77-91.
42. Schatzberg, A.F. Recent MRI studies in depression: Relationship to HPA axis activity. XXVI CINP Congr (July 13-17, Munich) 2008, S12.05.
43. Nemeroff, C. CRF, the neurobiology of depression and early life trauma: Implications for diagnosis and treatment. XXVI CINP Congr (July 13-17, Munich) 2008, S-12.02
44. Kehne, J.H. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007, 6(3): 163-82.
45. Heim, C., Newport, D.J., Mletzko, T., Miller, A.H. and Nemeroff, C.B. The link between childhood trauma and depression: Insights from HPA axis studies in humans. Psychoneuroendocrinology 2008, 33(6): 693-710.
46. Arborelius, L., Owens, M.J., Plotsky, P.M. and Nemeroff, C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999, 160(1): 1-12.
47. Tellew, J.E. and Luo, Z. Small molecule antagonists of the corticotropin releasing factor (CRF) receptor: recent medicinal chemistry developments. Curr Top Med Chem 2008, 8(6): 506-20.
48. Koob, G.F. and Heinrichs, S.C. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res 1999, 848(1-2): 141-52.
49. Vale, M., Perrin, M., Chen, A. et al. The role of corticotropin-releasing factor (CRF) and the HPA axis in the pathophysiology of depression. XXVI CINP Congr (July 13-17, Munich) 2008, S-12.
50. Ohata, H., Arai, K. and Shibasaki, T. Effect of chronic administration of a CRF(1) receptor antagonist, CRA1000, on locomotor activity and endocrine responses to stress. Eur J Pharmacol 2002, 457(2-3): 201-6.
51. Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R. and Stiger, T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008, 165(5): 617-20.
52. Hauger, R.L, Risbrough, V., Brauns, O. and Dautzenberg, F.M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 2006; 5(4): 453-79.
53. Pelleymounter, M.A., Joppa, M., Ling, N. and Foster, A.C. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 2002, 302(1): 145-52.
54. Tanaka, M. and Telegdy, G. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice. Brain Res Bull 2008, 75(5): 509-12.
55. Palucha, A. and Pilc, A. The involvement of glutamate in the pathophysiology of depression. Drug News Perspect 2005, 18(4): 262-68.
56. Nakanishi, S. Molecular diversity of glutamate receptors and implication for brain function. Science 1992, 258(5082): 597-603.
57. Conn, P.J. and Pin, J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37: 205-37.
58. Trullas, R. and Skolnick, P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990, 185(1): 1-10.
59. Maj, J., Skuza, G. and Rogóz, Z. Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. J Neural Transm Park Dis Dement Sect 1993, 6(1): 53-62.
60. Maj, J., Rogóz, Z. and Skuza, G. The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats. Pol J Pharmacol Pharm 1992, 44(3): 217-26.
61. Panconi, E., Roux, J., Altenbaumer, M., Hampe, S. and Porsolt, R.D. MK-801 and enantiomers: potential antidepressants or false positives in classical screening models? Pharmacol Biochem Behav 1993, 46(1): 15-20.
62. Ossowska, G., Klenk-Majewska, B. and Szymczyk, G. The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats. J Physiol Pharmacol 1997, 48(1): 127-35.
63. Papp, M., Moryl, E. and Willner, P. Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 1996, 296(2): 129-36.
64. Redmond, A.M., Kelly, J.P. and Leonard, B.E. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 1997, 58(2): 355-9.
65. Danysz, W., Parson, C.G., Bersnick, I. and Quack, G. Glutamate in CNS disorders. Drug News Perspect 1996, 8: 261-77.
66. Parsons, C.G., Danysz, W. and Quack, G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999, 38(6): 735-67.
67. Liebrenz, M., Borgeat, A., Leisinger, R. and Stohler, R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly 2007, 137(15-16): 234-6.
68. Berman, R.M., Cappiello A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S. and Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47(4): 351-4.
69. Manji, H.K., Chen, G., Salvadore, G., Duncan, W., Du, J. and Zarate, C. Targetting remission: Strategies to enhance the therapeutic efficacy of antidepressants. XXVI CINP Congr (July 13-17, Munich) 2008, S-05.
70. Popik, P., Kos, T., Sowa-Kucma, M. and Nowak, G. Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) 2008, 198(3): 421-30.
71. Skolnick, P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375 (1-3): 31-40.
72. Nibuya, M., Morinobu, S. and Duman, R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995, 15(11): 7539-47.
73. Brandoli, C., Sanna, A., De Bernardi, M.A., Follesa, P., Brooker, G. and Mocchetti, I. Brain-derived neurotrophic factor and basic fibroblast growth factor downregulate NMDA receptor function in cerebellar granule cells. J Neurosci 1998, 18(19): 7953-61.
74. Chourbaji, S., Vogt, M.A., Fumagalli, F. et al. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J 2008, 22(9): 3129-34.
75. Bai, F., Bergeron, M. and Nelson, D.L. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 2003, 44(8): 1013-21.
76. Pilc, A., Klodzinska, A., Branski, P. et al. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 2002, 43(2): 181-7.
77. Attucci, S., Carla, V., Mannaioni, G. and Moroni, F. Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br J Pharmacol 2001, 132(4): 799-806.
78. Chaki, S., Yoshikawa, R., Hirota, S. et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004, 46(4): 457-67.
79. Yoshimizu, T. and Chaki, S. Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun 2004, 315(2): 493-6.
80. Palucha, A., Tatarczynska, E., Branski, P. et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004, 46(2): 151-9.
81. Flores, B.H., Kenna, H., Keller, J., Solvason, H.B. and Schatzberg, A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006, 31(3): 628-36.
82. Schatzberg, A.F. and Belanoff, J. Glucocorticoid receptor antagonists as a novel treatment option in psychotic depression. XXVI CINP Congr (July 13-17, Munich) 2008, S-20.03.
83. Smith, R. The macrophage theory of depression. Med Hypothesis 1991, 35: 298-306.
84. Leonard, B. Mechanisms of inflammation in major depression. XXVI CINP Congr (July 13-17, Munich) 2008, S-33.02.
85. Song, C. The role of cytokines in depression: An insight of the relationship between inflammation and neurotrophic factors. XXVI CINP Congr (July 13-17, Munich) 2008, S-33.03.
86. Connor, T. Anti-inflammatory actions of antidepressants: Relevance to the treatment of psychiatric and neurological disorder. XXVI CINP Congr (July 13-17, Munich) 2008, S-33.04.
87. Myint, A.M., Steinbusch, H.W., Goeghegan, L., Luchtman, D., Kim, Y.K. and Leonard, B.E. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007, 14(2): 65-71.
88. Müller, N., Schwarz, M.J. Dehning, S. et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11(7): 680-4.
89. Tadic, A. and Lieb, K. Pharmacological therapy for therapy-resistant depression. New developments. Nervenarzt 2007, 78(3): 551-63.
90. Lerer, B., Cooper-Kazaz, R., Lifschytz, T. et al. Enhancement of antidepressant effects with triiodothyronine: Clinical evidence and neurobiological mechanisms. XXVI CINP Congr (July 13-17, Munich) 2008, S-05.03.
91. Iosifescu, D.V. Bolo, N.R., Nierenberg, A.A., Jensen, J.E., Fava, M. and Renshaw, P.F. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry 2008, 63(12): 1127-34.
92. Cooper-Kazaz, R. and Lerer, B. Efficacy and safety of triiodothvronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008, 11(5): 685-99.
93. Gass, P. and Riva, M.A. CREB, neurogenesis and depression. Bioessays 2007, 29(10): 957-61.
94. Tanis, K.Q., Duman, R.S. and Newton, S.S. CREB binding and activity in brain: regional specificity and induction by electroconvulsive seizure. Biol Psychiatry 2008, 63(7): 710-20.
95. Conti, A.C., Cryan, J.F., Dalvi, A., Lucki, I. and Blendy, J.A. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002, 22(8): 3262-8.
96. Blendy, J.A. CREB-deficiency allows for increased neurogenesis in mice and a rapid onset of antidepressant response. XXVI CINP Congr (July 13-17, Munich) 2008, S-04.03.
97. Qi, X., Lin, W., Li, J., Li, H., Wang, W., Wang, D. and Sun, M. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis 2008, 31(2): 278-85.
98. Fitzgerald, P. Brain stimulation techniques for the treatment of depression and other psychiatric disorders. Australas Psychiatry 2008, 16(3): 183-90.
99. McLoughlin, D. Will brain stimulation techniques improve therapeutic outcome in depression? XXVI CINP Congr (July 13-17, Munich) 2008, S-05.05.
100. Padberg, F. and Möller, H.J. Repetitive transcranial magnetic stimulation: does it have potential in the treatment of depression? CNS Drugs 2003, 17(6): 383-403.
101. Harkin, A. MDMA Ecstasy-induced serotonin loss. Implications for depressive and anxiety disorders. XXVI CINP Congr (July 13-17, Munich) 2008, S-09.05.
102. Andrews, G., Hall, W., Goldstein, G., Lapsley, H., Bartels, R. and Silove, D. The economic costs of schizophrenia. Implications for public policy. Arch Gen Psychiatry 1985, 42(6): 537-43.
103. Andreasen, N.C., Flaum, M., Swayze, V.W., Tyrrell, G. and Arndt, S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch-Gen Psychiatry 1990, 47(7): 615-21.
104. Delay, J. and Deniker, P. Trenle-huit cas de psychoses traities par la cure prologue et continue de 4560 RP. Le Congres des Al. Et Neurol. De Langue Fr. In: Compte rendu du Congres. Masson et Cie, Paris, 1952.
105. Herings, R.M. and Erkens, J.A. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003, 12(5): 423-4.
106. Tiihonen, J., Walhbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J.P., Volavka, J. and Haukka, J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006, 333(7561): 224.
107. Kane, J. The role of novel depot formulations. XXVI CINP Congr (July 13-17, Munich) 2008, IS-01.
108. Bitter, I. The importance of long-term treatment. XXVI CINP Congr (July 13-17, Munich) 2008, IS-01.
109. Wildeboer, K.M. and Stevens, K.E. Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice. Brain Res 2008, 1224: 29-36.
110. Simosky, J.K., Stevens, K.E., Adler, L.E. and Freedman, R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl). 2003, 165(4): 386-96.
111. Piser, T. Neuronal nicotinic receptor modulating drugs targeting schizophrenia. XXVI CINP Congr (July 13-17, Munich) 2008, S-18.03.
112. Hajós, M., Hurst, R.S., Hoffmann, W.E., Krause, M., Wall, T.M., Higdon, N.R. and Groppi, V.E. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 2005, 312(3): 1213-22.
113. Boess, F.G., De Vry, J., Erb, C. et al. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]- 7-[2-(methoxy)phenyl-1--benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 2007, 321(2): 716-25.
114. Pichat, P., Bergis, O.E., Terranova, J.P. et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007, 32(1): 17-34.
115. Svensson, T.H. Role of alpha adrenergic receptor antagonism in antipsychotic drug action. XXVI CINP Congr (July 13-17, Munich) 2008, S-18.02.
116. Zoccali, R., Muscatello, M.R., Torre, D.L. et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res 2003, 48(4): 411-4.
117. Schwarz, M.J., Riedel, M., Myint, A.M. and Mueller, N. The role of inflammation in psychiatric disorders. XXVI CINP Congr (July 13-17, Munich) 2008, S-33.01.
118. Liu, L., Jia, F.J. and Li, H.F. The mRNA expression levels of IL-1beta, TNF-alpha and tyrosine hydroxylase in peripheral blood of paranoid schizophrenic patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2007, 23(11): 1043-5.
119. Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R. and Kouassi, E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63(8): 801-8.
120. Müller, N. and Schwarz, M.J. Immunology in schizophrenic disorders. Nervenarzt 2007, 78(3): 253-6.
121. Akhondzadeh, S., Tabatabace, M., Amini, H., Ahmadi Abhari, S.A., Abbasi, S.H. and Behnam, B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007, 90(1-3): 179-85.
122. Müller, N., Riedel, M., Scheppach, C. et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002, 159(6): 1029-34.
123. Stolk, P., Souverein, P.C., Leufkens, H.G., Weil, J.G., Egberts, A.C. and Heerdink, E.R. The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study. Pharmacopsychiatry. 2007, 40(3): 111-5.